furosemide has been researched along with dapagliflozin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akimoto, T; Imai, T; Maeshima, A; Masuda, T; Miki, A; Miyazawa, Y; Murakami, T; Muto, S; Myoga, A; Nagata, D; Nakagawa, S; Ohara, K; Okada, M; Saito, O; Sekiguchi, C; Sugase, T; Yoshizawa, H | 1 |
| Nakamoto, K; Tsubakimoto, M; Yabiku, K | 1 |
| Chatur, S; Claggett, B; de Boer, RA; Desai, AS; Haddad, T; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Lam, CSP; Maria Langkilde, A; Martinez, F; McMurray, JJV; Miao, ZM; Mitter, SS; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M; Vardeny, O | 1 |
| Andreev, DA; Charaya, KV; Dimchishina, AS; Kusova, ZR; Mesitskaya, DF; Nikiforova, TV; Novikova, NA; Schekochikhin, DIY; Shkliarov, AM; Soboleva, TV | 1 |
| Andreev, DA; Charaya, KV; Dimchishina, AS; Kusova, ZR; Mesitskaya, DF; Nikiforova, TV; Novikova, NA; Schekochikhin, DY; Shkliarov, AM; Soboleva, TV | 1 |
2 trial(s) available for furosemide and dapagliflozin
| Article | Year |
|---|---|
The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left; Weight Loss | 2023 |
The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left; Weight Loss | 2023 |
3 other study(ies) available for furosemide and dapagliflozin
| Article | Year |
|---|---|
Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzhydryl Compounds; Body Composition; Female; Fluid Shifts; Furosemide; Glucosides; Humans; Male; Prospective Studies; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance; Water-Electrolyte Imbalance | 2019 |
Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
Topics: Animals; Ascites; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Diuresis; Drug Therapy, Combination; Furosemide; Glucosides; Hemodynamics; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
Topics: Benzhydryl Compounds; Diuretics; Furosemide; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Ventricular Function, Left | 2023 |